VII-31
VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways[1].
Product Specifications
CAS Number
2305757-96-2
UNSPSC
12352005
Target
Apoptosis; E1/E2/E3 Enzyme
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vii-31.html
Purity
99.63
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(CC1=CC=CS1)N(CC2=CC=C(OC)C=C2)C3=CC(OC)=C(OC)C(OC)=C3
Molecular Formula
C23H25NO5S
Molecular Weight
427.51
References & Citations
[1]Dong-Jun Fu, et al. Discovery of Novel Tertiary Amide Derivatives as NEDDylation Pathway Activators to Inhibit the Tumor Progression in Vitro and in Vivo. Eur J Med Chem. 2020 Apr 15;192:112153.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
034216-ML650 100 µL
CRELD2, NT (CRELD2, Cysteine-rich with EGF-like domain protein 2) (MaxLight 650) discontinued
Sign In for Pricing
View Details 